Obesity, insulin resistance, Type 2 diabetes and free fatty acids

References

• Bray GA. Medical consequences of obesity. J. Clin. Endocrinol. Metab.89, 2583–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes46, 3–10 (1997).
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA294, 334–341 (2005).
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka et al. Hypoadiponectinemia in obesity and Type 2 diabetes: a close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab.88, 1930–1935 (2001).
   Google Scholar
• Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab.86, 3815–3819 (2001).
   PubMed Web of Science ®Google Scholar
• Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes37, 1020–1024 (1988).
   PubMed Web of Science ®Google Scholar
• Boden G, Jadali F, White J et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J. Clin. Invest.88, 960–966 (1991).
   PubMed Web of Science ®Google Scholar
• Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes48, 1836–1841 (1999).
   PubMed Web of Science ®Google Scholar
• Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover in obesity. Acta. Med. Scand.185, 351–356 (1969).
   PubMedGoogle Scholar
• Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism obesity. J. Clin. Invest.83, 1168–1173 (1989).
   PubMed Web of Science ®Google Scholar
• Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am. J. Physiol.283, E12–E19 (2002).
   PubMed Web of Science ®Google Scholar
• Baron AD. Insulin resistance and vascular function. J. Diabetes Complications16, 92–102 (2002).
   PubMed Web of Science ®Google Scholar
• Zeng G, Nystrom FH, Ravichandran LV et al. Roles for insulin receptor, PI3-kinase and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation101, L1539–L1545 (2000).
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest.100, 1230–1239 (1997).
   PubMed Web of Science ®Google Scholar
• Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet1, 785–789 (1963).
   PubMed Web of Science ®Google Scholar
• Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J. Clin. Invest.96, 1261–1268 (1995).
   PubMed Web of Science ®Google Scholar
• Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J. Clin. Invest.103, 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Boden G, Lebed B, Schatz M, Homko C, Semieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes50, 1612–1617 (2001).
   PubMed Web of Science ®Google Scholar
• Itani SI, Ruderman NB, Schmieder, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes51, 2005–2011 (2002).
   PubMed Web of Science ®Google Scholar
• Farese R. Diabetes Mellitus: a Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM (Eds). Philadelphia, Lippincott, 239–251 (2000).
   Google Scholar
• Yu C, Chen Y, Cline GW et al. Mechanism by which fatty acids inhibit activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem.277, 50230–50236 (2002).
   PubMed Web of Science ®Google Scholar
• Boden G, She P, Mozzoli M et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes54, 3458–3465 (2005).
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes49, 1939–1945 (2000).
   PubMed Web of Science ®Google Scholar
• Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care26, 645–649 (2003).
   PubMed Web of Science ®Google Scholar
• Boden G. Free fatty acids and insulin secretion in humans. Current Diabetes Reports5, 167–170 (2005).
   PubMedGoogle Scholar
• Crespin SR, Greenough WB, Steinberg D. Stimulation of insulin secretion by longchain free fatty acids. J. Clin. Invest.52, 1979–1984 (1973).
   PubMedGoogle Scholar
• Hennes MMI, Dua A, Kissebah AH. Effects of free fatty acids and glucose on splanchnic insulin dynamics. Diabetes46, 57–62 (1997).
   PubMed Web of Science ®Google Scholar
• Balent B, Goswami G, Goodloe G et al. Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. Ann. NY. Acad. Sci.967, 535–543 (2002).
   PubMedGoogle Scholar
• Brown AJ, Jupe S, Briscoe CP. A family of fatty acid binding receptors. DNA Cell Biol.24, 54–61 (2005).
   PubMed Web of Science ®Google Scholar
• Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes44, 1239–1242 (1995).
   PubMed Web of Science ®Google Scholar
• Jensen CB, Storgaard H, Holst JJ, Dela F, Madsbad S, Vaag AA. Insulin secretion and cellular glucose metabolism after prolonged low-grade intralipid infusion in young men. J. Clin. Endocrinol. Metab.88, 2775–2783 (2003).
   PubMedGoogle Scholar
• Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetes. Diabetes52, 2461–2474 (2003).
   PubMed Web of Science ®Google Scholar
• Boden G, Chen X, Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetes and nondiabetic subjects. Diabetes47, 1609–1612 (1998).
   PubMedGoogle Scholar
• Dobbins RL, Chester MW, Daniels MB, McGarry DJ, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes47, 1613–1618 (1998).
   PubMed Web of Science ®Google Scholar
• Boden G, Soeldner JS, Gleason RE, Marble A. Elevated serum human growth hormone and decreased serum insulin in prediabetic males after intravenous tolbutamide and glucose. J. Clin. Invest.47, 729–739 (1968).
   PubMedGoogle Scholar
• Stogaard H, Jensen CB, Vaag A et al. Insulin secretion after short- and long-term low grade free fatty acid infusion in men with increased risk of developing Type 2 diabetes. Metabolism52, 885–894 (2003).
   PubMedGoogle Scholar
• Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in Type 2 diabetes. Diabetes48, 577–583 (1999).
   PubMedGoogle Scholar
• Hirose H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, Unger RH. Defective fatty acid mediated β-cell compensation in Zucker diabetic fatty rats. J. Biol. Chem.271, 5633–5637 (1996).
   PubMedGoogle Scholar
• Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes44, 863–870 (1995).
   PubMed Web of Science ®Google Scholar
• El-Assaad W, Buteau J, Peyot ML et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death. Endocrinology144, 4154–4163 (2003).
   PubMed Web of Science ®Google Scholar
• Tataranni PA, Ortega E. A burning question. Does an adipokines-induced activation of the immune system mediate the effect of overnutrition on Type 2 diabetes? Diabetes54, 917–927 (2005).
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and system insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med.11, 183–190 (2005).
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest.112, 1821–1830 (2003).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest.112, 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Fuccella LM, Goldaniga G, Lovisolo P et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin. Pharmacol. Ther.28, 790–795 (1980).
   PubMed Web of Science ®Google Scholar
• Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J. Clin. Invest.103, 365–372 (1999).
   PubMedGoogle Scholar
• Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with Type 2 diabetes. Metabolism52, 753–759 (2003).
   PubMed Web of Science ®Google Scholar
• Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes54, 880–885 (2005).
   PubMed Web of Science ®Google Scholar
• Ghazzi MN, Perez JE, Antonucci TK et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes46, 433–439 (1997).
   PubMed Web of Science ®Google Scholar
• Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in Type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.128, 176–185 (1998).
   PubMedGoogle Scholar
• Mayerson AB, Hundal RS, Dufour S. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes51, 797–802 (2002).
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Ann. Rev. Med.53, 409–435 (2002).
   PubMed Web of Science ®Google Scholar